Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ORACLE-RIPA: CDK4/6 inhibitors in early breast cancer
NCT05766410Phase 2Recruiting
- Sponsor
- National Taiwan University Hospital
- Start
- Sep 2022
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of palbociclib, ribociclib, abemaciclib in breast cancer, sponsored by National Taiwan University Hospital. Started Sep 2022; status: recruiting.
02
Drugs
palbociclibribociclibabemaciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05766410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05766410.